Clinical Trials /

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

NCT04930653

Description:

This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with a machine, isolates white blood cells and exposes them to ultra violet light, then returns the cells to the body. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving mogamulizumab with ECP may work together to kill the tumor cells directly (with mogamulizumab) and boost immune response to cancer (with ECP).

Related Conditions:
  • Mycosis Fungoides
  • Sezary Syndrome
  • Transformed Non-Hodgkin Lymphoma
Recruiting Status:

Not yet recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma
  • Official Title: A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL

Clinical Trial IDs

  • ORG STUDY ID: 20724
  • SECONDARY ID: NCI-2021-03533
  • SECONDARY ID: 20724
  • SECONDARY ID: P30CA033572
  • NCT ID: NCT04930653

Conditions

  • Folliculotropic Mycosis Fungoides
  • Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • Sezary Syndrome
  • Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8
  • Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8
  • Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8
  • Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
  • Transformed Mycosis Fungoides

Interventions

DrugSynonymsArms
MogamulizumabImmunoglobulin G1, Anti-(CC Chemokine Receptor CCR4) (Human-Mouse Monoclonal KW-0761 Heavy Chain), Disulfide With Human-Mouse Monoclonal KW-0761 Kappa-Chain, Dimer, KM8761, KW-0761, Mogamulizumab-kpkc, PoteligeoTreatment (ECP, mogamulizumab)

Purpose

This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL is a rare type of cancer that begins in the white blood cells called T cells. Erythrodermic is a widespread red rash that may cover most of the body. ECP is a medical treatment that removes blood with a machine, isolates white blood cells and exposes them to ultra violet light, then returns the cells to the body. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving mogamulizumab with ECP may work together to kill the tumor cells directly (with mogamulizumab) and boost immune response to cancer (with ECP).

Detailed Description

      PRIMARY OBJECTIVE:

      I. To assess tolerability and overall response rate (ORR) of the (ECP)/mogamulizumab regimen
      in CTCL patients previously untreated with mogamulizumab.

      SECONDARY OBJECTIVES:

      I. To estimate complete response (CR) rate, time to response, duration of response,
      progression free survival, and overall survival in CTCL patients treated with the
      ECP/mogamulizumab combination.

      II. To summarize the toxicities in CTCL patients treated with the ECP/mogamulizumab
      combination.

      EXPLORATORY OBJECTIVES:

      I. To assess quality of life (QoL) parameters before, during, and after the regimen.

      II. To evaluate the anti-tumor and immunomodulatory effects of mogamulizumab in the CTCL
      microenvironment in skin and blood samples of erythrodermic CTCL patients.

      III. To evaluate the immunomodulatory effects of ECP.

      OUTLINE:

      Patients receive mogamulizumab intravenously (IV) over 60 minutes on days 1, 8, 15, 22, of
      cycle 1 and days 1 and 15 of subsequent cycles. Beginning in cycle 2, patients also undergo
      ECP over 3 hours on days 8, 9, 22,and 23. Treatment repeats every 28 days for up to 6 cycles
      in the absence of disease progression or unacceptable toxicity. Patients achieving complete
      response (CR)/partial response (PR) after 6 cycles receive up to 6 additional cycles of
      treatment in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days, then for up to 12
      months.
    

Trial Arms

NameTypeDescriptionInterventions
Treatment (ECP, mogamulizumab)ExperimentalPatients receive mogamulizumab IV over 60 minutes on days 1, 8, 15, 22, of cycle 1 and days 1 and 15 of subsequent cycles. Beginning in cycle 2, patients also undergo ECP over 3 hours on days 8, 9, 22,and 23. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients achieving CR)/PR after 6 cycles receive up to 6 additional cycles of treatment in the absence of disease progression or unacceptable toxicity.
  • Mogamulizumab

Eligibility Criteria

        Inclusion Criteria:

          -  Documented informed consent of the participant and/or legally authorized
             representative

               -  Assent, when appropriate, will be obtained per institutional guideline

          -  Agreement to allow the use of archival tissue from diagnostic tumor biopsies

               -  If unavailable, exceptions may be granted with study principal investigator (PI)
                  approval

          -  Age: >= 18 years

          -  Eastern Cooperative Oncology Group (ECOG) =< 2

          -  Histologically confirmed mycosis fungoides (MF) or Sezary syndrome (SS). Safety
             lead-in: >= stage IIB OR >= stage IB-IIA folliculotropic/transformed MF. Phase 2: >=
             stage IB

               -  Stage of disease according to Tumor-Node-Metastasis-Blood (TNMB) classification

               -  Pathology report must be diagnostic or be consistent with MF/SS criteria

               -  SS is defined as meeting T4 plus B2 criteria; where the biopsy of erythrodermic
                  skin may only reveal suggestive but not diagnostic histopathologic features, the
                  diagnosis may be based on either node biopsy or fulfillment of B2 criteria

               -  For MF where the histological diagnosis by light microscopic examination is not
                  confirmed, diagnostic criteria that been recommended by the International Society
                  of Cutaneous Lymphomas (ISCL) should be used.

          -  Measurable disease per Modified Severity Weighted Assessment Tool (mSWAT) and/or
             Sezary count

          -  Baseline skin biopsy taken within 6 months available for central review submission

          -  Without bone marrow involvement: Absolute neutrophil count (ANC) >= 1,500/mm^3
             (performed within 7 days prior to day 1 of protocol therapy unless otherwise stated)

               -  NOTE: Growth factor is not permitted within 14 days of ANC assessment unless
                  cytopenia is secondary to disease involvement

          -  With bone marrow involvement: ANC >= 1,000/mm^3 (performed within 7 days prior to day
             1 of protocol therapy unless otherwise stated)

               -  NOTE: Growth factor is not permitted within 14 days of ANC assessment unless
                  cytopenia is secondary to disease involvement

          -  Without bone marrow involvement: Platelets >= 100,000/mm^3 (performed within 7 days
             prior to day 1 of protocol therapy unless otherwise stated)

               -  NOTE: Platelet transfusions are not permitted within 14 days of platelet
                  assessment unless cytopenia is secondary to disease involvement

          -  With bone marrow involvement: Platelets >= 75,000/mm3 (performed within 7 days prior
             to day 1 of protocol therapy unless otherwise stated)

               -  NOTE: Platelet transfusions are not permitted within 14 days of platelet
                  assessment unless cytopenia is secondary to disease involvement

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN) (unless has Gilbert's
             disease)(performed within 7 days prior to day 1 of protocol therapy unless otherwise
             stated)

          -  Aspartate aminotransferase (AST) =< 2.5 x ULN (unless has Gilbert's disease)(performed
             within 7 days prior to day 1 of protocol therapy unless otherwise stated)

          -  Alanine aminotransferase (ALT) =< 2.5 x ULN (unless has Gilbert's disease)(performed
             within 7 days prior to day 1 of protocol therapy unless otherwise stated)

          -  Creatinine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault
             formula (unless has Gilbert's disease) (performed within 7 days prior to day 1 of
             protocol therapy unless otherwise stated)

          -  If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin
             (PT) =< 1.5 x ULN (performed within 7 days prior to day 1 of protocol therapy unless
             otherwise stated)

          -  If on anticoagulant therapy: PT must be within therapeutic range of intended use of
             anticoagulants (performed within 7 days prior to day 1 of protocol therapy unless
             otherwise stated)

          -  If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) =< 1.5 x
             ULN (performed within 7 days prior to day 1 of protocol therapy unless otherwise
             stated)

          -  If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of
             anticoagulants (performed within 7 days prior to day 1 of protocol therapy unless
             otherwise stated)

          -  Hepatitis C virus (HCV)*, active hepatitis B virus (HBV) (surface antigen negative),
             and syphilis (rapid plasma reagin [RPR])

               -  If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed

          -  Meets other institutional and federal requirements for infectious disease titer
             requirements

               -  Note Infectious disease testing to be performed within 28 days prior to day 1 of
                  protocol therapy

          -  Subjects with MF and a history of staphylococcus colonization are eligible provided
             they continue to receive stable doses of prophylactic antibiotics

          -  Women of childbearing potential (WOCBP): negative urine or serum pregnancy test If the
             urine test is positive or cannot be confirmed as negative, a serum pregnancy test will
             be required

          -  Agreement by females and males of childbearing potential* to use an effective method
             of birth control or abstain from heterosexual activity for the course of the study
             through at least 3 months after the last dose of protocol therapy

               -  Childbearing potential defined as not being surgically sterilized (men and women)
                  or have not been free from menses for > 1 year (women only)

        Exclusion Criteria:

          -  Prior mogamulizumab

          -  Any systemic therapy, including monoclonal antibody within 28 days or 5 half-lives
             (whichever is shorter) of initiating protocol therapy

          -  Chemotherapy, radiation therapy, biological therapy, immunotherapy within 21 days
             prior to day 1 of protocol therapy

          -  Any skin-directed therapy within 14 days prior to initiating protocol therapy

          -  Any radiation therapy within 21 days prior to initiating protocol therapy

          -  Immunosuppressive medication within 14 days prior to the first dose of study
             treatment. The following are exceptions to this criterion:

               -  Intranasal, inhaled, topical or local steroid injections (e.g., intra-articular
                  injection) and are on stable dose for at least 28 days

               -  Systemic corticosteroids at physiologic doses of < 10 mg/day of prednisone or
                  equivalent

          -  Live, attenuated vaccine within 30 days prior to the first dose protocol therapy

          -  Disease free of prior malignancies for >= 5 years with the exception of:

               -  Currently treated squamous cell and basal cell carcinoma of the skin, or

               -  Carcinoma in situ of the cervix, or

               -  Surgically removed melanoma in situ of the skin (stage 0) with histological
                  confirmed free margins of excision, or

               -  Prostate cancer (T1a or T1b using the TNM [tumor, nodes, metastasis] clinical
                  staging system) that has/have been surgically cured, or

               -  Any other malignancy that has/have been curatively treated with surgery and/or
                  localized radiation

          -  Active infection requiring antibiotics

          -  Known hepatitis B or hepatitis C infection

          -  Other active malignancy

          -  Females only: Pregnant or breastfeeding

          -  Prior stem cell transplantation

          -  Acute infection requiring systemic treatment

          -  Conditions requiring chronic steroid or immunosuppressive treatment that likely need
             additional steroid or immunosuppressive treatments in addition to the protocol therapy

          -  Renal failure requiring hemodialysis or peritoneal dialysis

          -  Unstable cardiac disease as defined by one of the following:

               -  Cardiac events such as myocardial infarction (MI) within the past 6 months

               -  NYHA (New York Heart Association) heart failure class III-IV

               -  Uncontrolled atrial fibrillation or hypertension

          -  Major surgery (as defined by the investigator) within the 28 days prior to the first
             dose of study treatment

          -  Active or prior documented autoimmune or inflammatory disorders requiring therapy
             within the past 3 years prior to the start of treatment. The following are exceptions
             to this criterion:

               -  Vitiligo or alopecia

               -  Hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone
                  replacement; or

               -  Psoriasis not requiring systemic treatment

          -  History of primary immunodeficiency

          -  Any other condition that would, in the Investigator's judgment, contraindicate the
             patient's participation in the clinical study due to safety concerns with clinical
             study procedures.

          -  Prospective participants who, in the opinion of the investigator, may not be able to
             comply with all study procedures (including compliance issues related to
             feasibility/logistics)
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Overall response rate (ORR)
Time Frame:Up to 1 year post treatment
Safety Issue:
Description:ORR will be calculated as the proportion of evaluable patients that have confirmed complete response (CR) or partial response (PR), as defined according to global response assessment. Exact 95% confidence intervals will be calculated for these estimates.

Secondary Outcome Measures

Measure:Complete response rate
Time Frame:Up to 1 year post treatment
Safety Issue:
Description:Defined as the proportion of response-evaluable patients that have a documented CR.
Measure:Time to response
Time Frame:From initiation of study therapy to the first achievement of CR or PR, assessed up to 1 year
Safety Issue:
Description:Will be estimated using the product-limit method of Kaplan and Meier.
Measure:Duration of response
Time Frame:From the first achievement of PR or CR to time of partial disease or death, assessed up to 1 year
Safety Issue:
Description:Will be estimated using the product-limit method of Kaplan and Meier.
Measure:Progression-free survival
Time Frame:From initiation of study therapy to the first observation of disease relapse/progression or death from any cause, whichever occurs first, assessed up to 1 year
Safety Issue:
Description:Will be estimated using the product-limit method of Kaplan and Meier.
Measure:Overall survival
Time Frame:From initiation of study therapy to death from any cause, assessed up to 1 year
Safety Issue:
Description:Will be estimated using the product-limit method of Kaplan and Meier.
Measure:Incidence of adverse events
Time Frame:Up to 30 days post treatment
Safety Issue:
Description:Toxicity and adverse events will be recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events 5.0 scale. Observed toxicities will be summarized by type, severity, date of onset, and attribution.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:City of Hope Medical Center

Last Updated

June 18, 2021